SCHEMBL20215535

SCHEMBL20215535

CC(=O)N[C@H](CN1CCCC1)[C@H](O[Si](C)(C)C(C)(C)C)c1ccc2c(c1)OCCO2

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 7/20 0.50
HTR1A P08908 1/20 0.50
PTGS1 P23219 1/20 0.50
OPRM1 P35372 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MCL1 Q07820 1/20 0.38
HTT P42858 3/20 0.38
ACACB O00763 5/20 0.38
TSHR P16473 1/20 0.38
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
OGA O60502 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25797597 1.00 UGCG (0.50) UGCGHTR1APTGS1OPRM1L3MBTL1
SCHEMBL17996602 0.93 UGCG (0.49) UGCGHTR1APTGS1OPRM1L3MBTL1
SCHEMBL16595700 0.91 UGCG (0.47) UGCGHTR1APTGS1OPRM1L3MBTL1
SCHEMBL25797566 0.90 UGCG (0.53) UGCGHTR1APTGS1OPRM1L3MBTL1
SCHEMBL20215543 0.90 UGCG (0.53) UGCGHTR1APTGS1OPRM1L3MBTL1
SCHEMBL16595697 0.90 UGCG (0.50) UGCGHTR1APTGS1OPRM1L3MBTL1
SCHEMBL17996601 0.86 UGCG (0.43) UGCGHTR1APTGS1OPRM1L3MBTL1
SCHEMBL20204307 0.86 UGCG (0.71) UGCGHTR1APTGS1OPRM1KDM4E
SCHEMBL20204305 0.86 UGCG (0.71) UGCGHTR1APTGS1OPRM1KDM4E
SCHEMBL16595626 0.86 UGCG (0.55) UGCGHTR1APTGS1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200031808-A1 PROCESS FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2020-01-30 US disclosed
US-9988364-B1 Process for synthesis of Eliglustat and intermediate compounds thereof ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2018-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031808-A1 PROCESS FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF COASY, ELL, CYP3A4 UGCG 442/4885HTR1A 4060/4885PTGS1 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.